Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2017

Zeng Shu-Xiong, Zhu Yanjun, Ma Ai-Hong, Yu Weimin, Zhang Hongyong, Lin Tzu-Yin, Shi Wei, Tepper Clifford G, Henderson Paul T, Airhart Susan, Guo Jian-Ming, Xu Chuan-Liang, deVere White Ralph W, Pan Chong-Xian

Abstract excerpt

Purpose: Activation of the PI3K pathway occurs in over 40% of bladder urothelial cancers. The aim of this study is to determine the therapeutic potential, the underlying action, and the resistance mechanisms of drugs targeting the PI3K pathway.Experimental Design: Urothelial cancer cell lines and patient-derived xenografts (PDXs) were analyzed for alterations of the PI3K pathway and for their sensitivity to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Gemcitabine

Share to Indazoles

Share to Phosphatidylinositol 3-Kinase

Share to Sulfonamides

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28808038
DOI: 10.1158/1078-0432.CCR-17-0033
PMCID: PMC5668181

Genes

LSP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.PMID 28808038Read ↗

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.Semantic proximity Read ↗

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.Semantic proximity Read ↗

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.Semantic proximity Read ↗

Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunitiesSemantic proximity Read ↗

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.Semantic proximity Read ↗

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.Semantic proximity Read ↗

The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancerSemantic proximity Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progressionSemantic proximity Read ↗

CKS2 promotes the malignant phenotypes of bladder cancer cells via PI3K/AKT signaling pathway activation.Semantic proximity Read ↗

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial TumorsSemantic proximity Read ↗

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.